Vericel
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 314
- Market Cap
- $2.6B
- Introduction
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
MediWound Initiates Phase III Trial of EscharEx for Venous Leg Ulcers
• MediWound has commenced a Phase III clinical trial (VALUE) to evaluate EscharEx for the treatment of venous leg ulcers (VLUs).
• The VALUE trial is a randomized, double-blind, placebo-controlled study across 40 sites in the U.S. and Europe, enrolling 216 patients.
• EscharEx has shown promise in Phase II trials, demonstrating effective and rapid debridement of chronic wounds, potentially redefining VLU treatment.
• An interim analysis of the VALUE trial is expected in mid-2026, with strategic collaborations in place to ensure consistent wound management.
FDA Approves Arthroscopic Delivery for MACI Knee Cartilage Repair
• The FDA has approved a supplemental Biologics License Application for arthroscopic delivery of MACI, an autologous cultured chondrocytes on a porcine collagen membrane, for knee cartilage repair.
• This approval expands MACI's delivery options, offering a less invasive arthroscopic approach for repairing symptomatic cartilage defects up to 4 cm2.
• MACI Arthro is the only restorative biologic cartilage repair product approved for arthroscopic administration, potentially increasing market penetration.
• Vericel Corporation anticipates that MACI Arthro will support sustained revenue growth by addressing a larger segment of the treatable market.
FDA Approves NexoBrid for Pediatric Thermal Burn Treatment
• The FDA has approved NexoBrid (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and full-thickness thermal burns.
• This approval is based on the Phase 3 CIDS trial and other pediatric data, offering a non-surgical option for severe burn injuries in children.
• NexoBrid, a biologic product containing proteolytic enzymes, is now available for both adult and pediatric patients for eschar removal.
• Vericel anticipates expanding its customer base to include approximately 20 pediatric burn centers in the United States.
© Copyright 2025. All Rights Reserved by MedPath